Zobrazeno 1 - 10
of 19 848
pro vyhledávání: '"non-small cell lung cancer(nsclc)"'
Publikováno v:
Journal of the National Cancer Center, Vol 4, Iss 4, Pp 289-298 (2024)
Immune checkpoint inhibitors (ICIs) have significantly improved outcomes for patients with advanced driver-negative non-small cell lung cancer (NSCLC). However, targeted therapy remains the preferred treatment for advanced driver-positive NSCLC, incl
Externí odkaz:
https://doaj.org/article/759bf25ca9734a26938c418738d8b658
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Objective There is currently no consensus over whether neoadjuvant immunochemotherapy is more effective in young patients than in elderly patients with IIA–IIIB non-small-cell lung cancer (NSCLC). In this study, we compare the efficacy and
Externí odkaz:
https://doaj.org/article/57666b90b1f04180925d5a6687b6a848
Autor:
Fernando Henrique de Albuquerque Maia, Karina Gondim Moutinho da Conceição Vasconcelos, Heloisa de Andrade Carvalho, Patrícia Coelho de Soárez
Publikováno v:
BMC Health Services Research, Vol 24, Iss 1, Pp 1-14 (2024)
Abstract Background Lung cancer is one of the leading causes of morbidity and mortality in Brazil. Radiotherapy is an important therapeutic option, but the techniques used remain subjects of discussion. In this study, we compared the costs of convent
Externí odkaz:
https://doaj.org/article/3beb3eb515e04aafaf86935aa825ec7e
Autor:
Pin-Ching Hu, Jing-Yang Huang, Ya-Fu Cheng, Ching-Yuan Cheng, Chang-Lun Huang, Wei-Heng Hung, Bing-Yen Wang
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract The standard treatment guideline for stage IIIA/N2 non-small cell lung cancer (NSCLC) remains controversial despite years of research, and the necessity of surgery is still debated. This study aims to explore optimal treatment and surgical m
Externí odkaz:
https://doaj.org/article/b0b34df6b52b4a5886822f6fa1483369
Autor:
Parneet K. Cheema, Paul F. Wheatley-Price, Matthew J. Cecchini, Peter M. Ellis, Alexander V. Louie, Sara Moore, Brandon S. Sheffield, Jonathan D. Spicer, Patrick James Villeneuve, Natasha B. Leighl
Publikováno v:
Current Oncology, Vol 31, Iss 11, Pp 6979-6999 (2024)
Therapeutic strategies for early-stage non-small cell lung cancer (NSCLC) are advancing, with immune checkpoint inhibitors (ICIs) and targeted therapies making their way into neoadjuvant and adjuvant settings. With recent advances, there was a need f
Externí odkaz:
https://doaj.org/article/234336a74a674bd18fa75f41a4f0977a
Autor:
Min Sang Kim, Hyesun Jeong, Byeong Hyeon Choi, Jiho Park, Gun Seop Shin, Jik-Han Jung, Hyunku Shin, Ka-Won Kang, Ok Hwa Jeon, Jewon Yu, Ji-Ho Park, Yong Park, Yeonho Choi, Hyun Koo Kim, Sunghoi Hong
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-16 (2024)
Abstract Fundamental changes in intracellular processes, such as overactive growth signaling pathways, are common in carcinomas and are targets of many cancer therapeutics. GRIP and coiled-coil containing 2 (GCC2) is a trans-Golgi network (TGN) golgi
Externí odkaz:
https://doaj.org/article/d86a232693564cf5b999a5925025e403
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 5, Iss 6, Pp 1297-1320 (2024)
Lung cancer is the leading cause of cancer mortality globally, with non-small cell lung cancer (NSCLC) accounting for 85% of cases. Despite advancements in first-line treatments such as immunotherapy and targeted therapies, resistance to these treatm
Externí odkaz:
https://doaj.org/article/b2f01ff1c3c241158e28a564b26abd28
Autor:
An Wang, Tao Li, Yun-ye Mao, Ming Gao, Sheng Shu, Chang-hong Xia, Yi Dong, Min Liu, Jin-liang Wang, Jun-xun Ma, Yi Hu
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-15 (2024)
Abstract Objective The present study endeavors to furnish an exhaustive review of the research advancements on solid tumors harboring RET rearrangement within the Chinese context, particularly emphasizing the examination of real-world therapeutic str
Externí odkaz:
https://doaj.org/article/14da8b0790fc4a759a33afbba168afbc
Autor:
Daniel Breadner, David M. Hwang, Don Husereau, Parneet Cheema, Sarah Doucette, Peter M. Ellis, Shaqil Kassam, Natasha Leighl, Donna E. Maziak, Shamini Selvarajah, Brandon S. Sheffield, Rosalyn A. Juergens
Publikováno v:
Current Oncology, Vol 31, Iss 10, Pp 6017-6031 (2024)
Lung cancer is the leading cause of cancer-related deaths in Canada, with non-small-cell lung cancer (NSCLC) accounting for the majority of cases. Timely access to comprehensive molecular profiling is critical for selecting biomarker-matched targeted
Externí odkaz:
https://doaj.org/article/f7cb34653c054cd781905d065bb3e78f
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-9 (2024)
Abstract Purpose Immune checkpoint inhibitors (ICIs) have improved lung cancer treatment but are associated with immune-related adverse events (irAEs). This study analyzes the relationship between irAEs and treatment effectiveness in advanced non-sma
Externí odkaz:
https://doaj.org/article/24f89ff893744ad6999c19926809fba4